Status:
COMPLETED
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
Lead Sponsor:
University Hospital, Ghent
Collaborating Sponsors:
Novartis
Conditions:
Vitiligo Vulgaris
Eligibility:
All Genders
6+ years
Phase:
PHASE2
Brief Summary
Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference ...
Eligibility Criteria
Inclusion
- Active or stable vitiligo vulgaris
- lesions at head or neck + maximum 10% lesions at the rest of the body
Exclusion
- Topica during last 2 weeks
- Photo(chemo)therapy during last 4 weeks
- Segmentary vitiligo
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
November 1 2004
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00372307
Start Date
May 1 2004
End Date
November 1 2004
Last Update
December 28 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ghent
Ghent, Belgium, 9000